GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARS Pharmaceuticals Inc (NAS:SPRY) » Definitions » Total Inventories

SPRY (ARS Pharmaceuticals) Total Inventories : $0.72 Mil (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is ARS Pharmaceuticals Total Inventories?

ARS Pharmaceuticals's total inventories for the quarter that ended in Sep. 2024 was $0.72 Mil. ARS Pharmaceuticals's average total inventories from the quarter that ended in Jun. 2024 to the quarter that ended in Sep. 2024 was $0.36 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. ARS Pharmaceuticals's Net-Net Working Capital per share for the quarter that ended in Sep. 2024 was $1.94.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. ARS Pharmaceuticals's Days Inventory for the three months ended in Sep. 2024 was 291.27.

Inventory Turnover measures how fast the company turns over its inventory within a year. ARS Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2024 was 0.31.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. ARS Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Sep. 2024 was 0.17.


ARS Pharmaceuticals Total Inventories Historical Data

The historical data trend for ARS Pharmaceuticals's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARS Pharmaceuticals Total Inventories Chart

ARS Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Inventories
- - - -

ARS Pharmaceuticals Quarterly Data
Dec20 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 0.72

ARS Pharmaceuticals Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


ARS Pharmaceuticals  (NAS:SPRY) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

ARS Pharmaceuticals's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2024 is

Net-Net Working Capital Per Share (Q: Sep. 2024 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(204.624+0.75 * 0.773+0.5 * 0.715-16.623
-0-0)/97.1474
=1.94

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

ARS Pharmaceuticals's Days Inventory for the three months ended in Sep. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Sep. 2024 )/Cost of Goods Sold (Q: Sep. 2024 )*Days in Period
=0.3575/0.112*365 / 4
=291.27

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

ARS Pharmaceuticals's Inventory Turnover for the quarter that ended in Sep. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Sep. 2024 ) / Average Total Inventories (Q: Sep. 2024 )
=0.112 / 0.3575
=0.31

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

ARS Pharmaceuticals's Inventory to Revenue for the quarter that ended in Sep. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=0.3575 / 2.068
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


ARS Pharmaceuticals Total Inventories Related Terms

Thank you for viewing the detailed overview of ARS Pharmaceuticals's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


ARS Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
11682 El Camino Real, Suite 120, San Diego, CA, USA, 92130
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Executives
Laura Shawver director, officer: Chief Executive Officer 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Eric Karas officer: Chief Commercial Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Justin Chakma officer: Chief Business Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Richard E Lowenthal director, 10 percent owner, officer: President and CEO 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Sarina Tanimoto 10 percent owner, officer: Chief Medical Officer C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
James E Flynn director, 10 percent owner, other: Director by deputization 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Kathleen D. Scott officer: Chief Financial Officer C/O CONATUS PHARMACEUTICALS INC., 16745 WEST BERNARDO DRIVE, SUITE 200, SAN DIEGO CA 92127
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Peter A. Thompson director C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Brian Dorsey officer: Chief Operating Officer C/O SOMAXON PHARMACEUTICALS, INC., 10935 VISTA SORRENTO PARKWAY, SUITE 250, SAN DIEGO CA 92130
Ra Capital Healthcare Fund Lp director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Alexander A Fitzpatrick officer: Chief Legal Officer 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121
Orbimed Capital Gp Vi Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Rajeev Dadoo director C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 120, SAN DIEGO CA 92130
Pratik Shah director, 10 percent owner 3366 N. TORREY PINES COURT, SUITE 220, LA JOLLA CA 92037